Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024.

CHICAGO, Sept 30 (Reuters) - Clear evidence this week that Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab drug lecanemab slows cognitive decline in early stage dementia has ...

Eisai Co. said a volunteer died while using the company’s experimental Alzheimer’s drug lecanemab in a clinical trial, but that it wasn’t clear if the death was directly caused by the drug.

Eisai Europe’s headquarters were expanded to become Eisai Europe, Middle East, Africa and Russia in March 2012. Gary joined Eisai in 2008 as European Commercial Development Director.